Starpharma Holdings Ltd
PQ6
Company Profile
Business description
Starpharma Holdings Ltd is an Australian biotechnology company focused on developing targeted oncology therapeutics, including radiopharmaceuticals, using its clinically validated DEP (Dendrimer Enhanced Product) drug delivery platform. Leveraging more than 20 years of dendrimer expertise, it is advancing novel, proprietary assets and strategic partnerships aimed at improving patient outcomes.
Contact
4-6 Southampton Crescent
Abbotsford
MelbourneVIC3067
AUST: +61 385322700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
50
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
The stocks of these high-quality companies look cheap today.
stocks
Surge in combat drones drives upgrade for ASX share
Drone demand powers growth but investor optimism is overdone.
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
The market’s negative reaction to the announcement signals that investors, much like us, are not super excited about Meta’s prospects in the enterprise market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,859.20 | 4.50 | 0.05% |
| CAC 40 | 7,834.10 | 63.09 | -0.80% |
| DAX 40 | 25,254.21 | 23.01 | 0.09% |
| Dow JONES (US) | 51,267.90 | 90.94 | 0.18% |
| FTSE 100 | 10,497.94 | 35.99 | 0.34% |
| HKSE | 24,040.34 | 68.05 | 0.28% |
| NASDAQ | 27,477.31 | 286.45 | 1.05% |
| Nikkei 225 | 69,946.86 | 1,637.40 | 2.40% |
| NZX 50 Index | 13,674.32 | 24.70 | -0.18% |
| S&P 500 | 7,773.95 | 51.23 | 0.66% |
| S&P/ASX 200 | 8,686.40 | 4.30 | 0.05% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |